global access to diabetes care

Closing the gap between the number of people who need diabetes care and those who receive it is a shared responsibility. Together with partners, we are accelerating our efforts to change diabetes by improving access to diabetes care worldwide.

NUSAYBAH ABU HADID
Nusaybah has type 1 diabetes and lives in Jordan
Access to diabetes care – a global issue demanding local solutions

Non-communicable diseases (NCDs), including diabetes, are the leading cause of death in the world today. More than 382 million people are living with diabetes worldwide, and 4 out of 5 live in low- and middle-income countries with limited access to diabetes care.

Our key contribution is to discover and develop innovative biological medicines and make them accessible to people with diabetes throughout the world. We are committed to always having low-priced insulin in our product portfolio. We have set ourselves a long-term target of reaching 40 million people with our diabetes medicine by 2020 – our 40by20 target. 40by20 is also a contribution towards the World Health Organisation’s global NCD target, 25by25 – a 25% reduction in premature mortality from NCDs by 2025.

In the run up to 2020, we are scaling up activities in three cross-cutting areas:

1. Health for the next generation
   Promoting a life-course approach to caring for patients by focusing on disease prevention and access to care, particularly for women and children.

2. Reaching the base of the pyramid
   Developing innovative and sustainable models for diabetes care for the working poor.

3. Global education
   Contributing to the education of people with diabetes and the training of healthcare professionals globally to raise awareness of diabetes and build capacity to diagnose and treat the disease.

The diabetes ‘Rule of Halves’

Of the estimated 382 million people with diabetes, about 50% are diagnosed. Of whom about 50% receive care. Of whom about 50% achieve treatment targets. Of whom about 50% achieve desired outcomes. Actual rates of diagnosis, treatment, targets and outcomes vary in different countries.

Learn more about our efforts to improve global access to diabetes care at changingdiabetesaccess.com